Lexaria receives three new Australian patents
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) reports it has received three new Australian patents. The new patents are projected to expire on June 10, 2035. LXRP now holds a total of eight patents: four from the U.S. and four from Australia. All patents to date fall under its initial patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." In addition, LXRP has received two new Notices of Allowance for pending patent applications from the U.S. Patent & Trademark Office (USPTO) which is expected to result in new patents issued prior to the end of 2018. At the same time, two further patents are expected from Australia prior to the end of the year. LXRP has now filed a total of 50 patent applications across nine patent families and expects to file an additional seven new patents before the end of 2018 at which time it will be managing sixteen patent families (read full report here).
Although investor response to these patent announcements has been relatively modest, we think this is a mistake. LXRP is one of the few companies that seems to be looking beyond the current scramble in the cannabis industry. We believe the portfolio of Intellectual Property that LXRP is building will be a valuable asset and that will become obvious in the next six to eighteen months.